S. Russo

发表

Markers of the uPA system and common prognostic factors in breast cancer.

F. Puglisi, C. di Loreto, G. Damante, 2007, American journal of clinical pathology.

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First‐Line Exemestane: Results From a Prospective Study

M. Montico, R. Meo, F. Puglisi, 2019, Clinical breast cancer.

Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?

G. Fasola, A. Minisini, S. Russo, 2022, Frontiers in Oncology.

Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.

F. Puglisi, C. di Loreto, D. Crivellari, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR mutation detection by microfluidic technology: a validation study

G. Troncone, C. Bellevicine, S. Russo, 2013, Journal of Clinical Pathology.

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.

P. Valagussa, S. Russo, R. Greil, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

D. Bruzzese, G. Arpino, A. Fabi, 2020, ESMO open.

Factors affecting patient's perception of anticancer treatments side-effects: an observational study

G. Fasola, F. Puglisi, S. Russo, 2014, Expert opinion on drug safety.

Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: a personalized approach.

M. Pestrin, S. Russo, L. Nicolardi, 2022, Critical reviews in oncology/hematology.

Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.

G. Fasola, F. Puglisi, C. di Loreto, 2018, Future oncology.

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

F. Puglisi, G. Damante, G. Baldassarre, 2020, Frontiers in Oncology.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study

D. Bruzzese, G. Arpino, F. Montemurro, 2016, Journal of Cancer Research and Clinical Oncology.

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

P. Neven, R. Bose, H. Rugo, 2021, Breast Cancer Research and Treatment.

Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study.

G. Fasola, F. Puglisi, A. Minisini, 2020, Future oncology.

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

M. Ceppi, F. Puglisi, A. Ardizzoni, 2021, NPJ breast cancer.

Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy

G. Fasola, F. Puglisi, G. Damante, 2012, Anti-cancer drugs.

Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells

F. Puglisi, C. di Loreto, A. Minisini, 2007, Anti-cancer drugs.

Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial

R. Greil, B. Győrffy, Esther Danenberg, 2022, Cancer Research.

Measures of outcome in metastatic breast cancer: insights from a real-world scenario.

G. Fasola, F. Puglisi, A. Minisini, 2014, The oncologist.

EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer

G. Troncone, C. Bellevicine, S. Russo, 2015, Journal of Clinical Pathology.

Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications.

F Puglisi, A. Piga, F. Puglisi, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

F. Puglisi, G. Arpino, D. Generali, 2021, ESMO open.

Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study

Chiun-Sheng Huang, G. Viale, L. Gianni, 2020 .

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients

G. Troncone, C. Bellevicine, S. Russo, 2013, Cancer cytopathology.

Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial

R. Greil, D. Ross, B. Győrffy, 2022, Cancer Research.

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’

D. Bruzzese, G. Arpino, A. Fabi, 2021, ESMO Open.

Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study

G. Fasola, F. Puglisi, S. Russo, 2018, Journal of Cancer Research and Clinical Oncology.